Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $2,165,637.06 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 48,546 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $44.61, for a total value of $2,165,637.06. Following the completion of the sale, the director owned 2,916,228 shares of the company’s stock, valued at $130,092,931.08. This trade represents a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Price Performance

SION stock opened at $43.12 on Thursday. The business has a 50 day simple moving average of $39.11 and a 200-day simple moving average of $39.51. The firm has a market capitalization of $1.95 billion, a PE ratio of -22.34 and a beta of 1.35. Sionna Therapeutics, Inc. has a 1 year low of $11.77 and a 1 year high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, equities research analysts expect that Sionna Therapeutics, Inc. will post -2.32 EPS for the current year.

Sionna Therapeutics News Summary

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Sionna Therapeutics and kept a $58 price target, implying meaningful upside from recent trading levels and reinforcing optimism around the company’s clinical pipeline. Article Title
• Positive Sentiment: Sionna Therapeutics said management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20, which can give investors a fresh update on the company’s cystic fibrosis programs and keep attention on the story. Article Title
• Neutral Sentiment: In its first-quarter update, the company said enrollment is complete in the PreciSION CF Phase 2a trial for SION-719 and that topline data is expected in summer 2026, while the SION-451 Phase 1 study is also on track. It also reported a strong cash balance of about $289.9 million, supporting operations into 2028. Article Title
• Negative Sentiment: Sionna reported a first-quarter loss of $0.60 per share, wider than the expected $0.52 loss, which may weigh on sentiment even though the company remains pre-revenue and focused on clinical development. Article Title
• Negative Sentiment: Director OrbiMed Advisors and director Peter A. Thompson disclosed several large share sales in recent days. The transactions were made under pre-arranged 10b5-1 plans, but the size of the selling can still pressure investor sentiment. Article Title

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Walleye Capital LLC purchased a new position in Sionna Therapeutics in the first quarter worth approximately $605,000. AlphaCentric Advisors LLC grew its position in Sionna Therapeutics by 77.1% in the first quarter. AlphaCentric Advisors LLC now owns 4,818 shares of the company’s stock worth $193,000 after acquiring an additional 2,098 shares during the period. Jennison Associates LLC lifted its stake in Sionna Therapeutics by 30.1% during the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares in the last quarter. Candriam S.C.A. acquired a new position in Sionna Therapeutics during the first quarter worth $9,494,000. Finally, Strs Ohio acquired a new position in Sionna Therapeutics during the first quarter worth $116,000.

Wall Street Analysts Forecast Growth

SION has been the subject of several analyst reports. Guggenheim increased their price objective on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Wedbush initiated coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective for the company. Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. UBS Group reiterated a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.00.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.